Patents by Inventor Jeff Castelli

Jeff Castelli has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20210069161
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: October 22, 2020
    Publication date: March 11, 2021
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Dosing regimens for the treatment of lysosomal storage diseases using pharmacological chaperones
    Patent number: 10925866
    Abstract: The present invention provides dosing regimens for administering pharmacological chaperones to a subject in need thereof. The dosing regimens can be used to treat disorders caused by improper protein misfolding, such as lysosomal storage disorders.
    Type: Grant
    Filed: June 18, 2018
    Date of Patent: February 23, 2021
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, David J. Lockhart
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20210038581
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 11, 2021
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20210038583
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20210038582
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: October 23, 2020
    Publication date: February 11, 2021
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20210030730
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: October 22, 2020
    Publication date: February 4, 2021
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating fabry patients having renal impairment
    Patent number: 10874655
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10874657
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10874656
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 29, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10857142
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 8, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10857141
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 8, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10849889
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 1, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10849890
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: December 1, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating fabry patients having renal impairment
    Patent number: 10806727
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 20, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10799491
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 13, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10792279
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 6, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods of treating Fabry patients having renal impairment
    Patent number: 10792278
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: October 6, 2020
    Assignee: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Enhancing And/Or Stabilizing Cardiac Function In Patients With Fabry Disease
    Publication number: 20200222377
    Abstract: Provided are methods for the treatment of Fabry disease in a patient. Certain methods relate to the treatment of ERT-experienced or ERT-naïve Fabry patients. Certain methods comprise administering to the patient about 100 mg to about 150 mg free base equivalent of migalastat for enhancing and/or stabilizing cardiac function.
    Type: Application
    Filed: August 28, 2018
    Publication date: July 16, 2020
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Jay Barth, Nina Skuban
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20200222378
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 16, 2020
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin
  • Methods Of Treating Fabry Patients Having Renal Impairment
    Publication number: 20200206207
    Abstract: Provided are methods for treatment of Fabry disease in patients having HEK assay amenable mutations in ?-galactosidase A. Certain methods comprise administering migalastat or a salt thereof every other day, such as administering about 150 mg of migalastat hydrochloride every other day.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 2, 2020
    Applicant: Amicus Therapeutics, Inc.
    Inventors: Jeff Castelli, Elfrida Benjamin